scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1018796813 |
P356 | DOI | 10.1007/S10545-011-9346-0 |
P932 | PMC publication ID | 3174318 |
P698 | PubMed publication ID | 21556831 |
P5875 | ResearchGate publication ID | 51111981 |
P2093 | author name string | Frederick J Marshall | |
Erika F Augustine | |||
Jonathan W Mink | |||
Heather Adams | |||
Paul G Rothberg | |||
Elisabeth A de Blieck | |||
Jennifer Kwon | |||
Amy Vierhile | |||
Jennifer Cialone | |||
Nicole Newhouse | |||
P2860 | cites work | Spectrum of mutations in the Batten disease gene, CLN3 | Q24678552 |
CLN3, the protein associated with batten disease: structure, function and localization | Q28303139 | ||
Neuronal ceroid lipofuscinoses in childhood | Q34080022 | ||
Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons | Q34121060 | ||
Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease | Q35216601 | ||
Homogeneous polymerase chain reaction nucleobase quenching assay to detect the 1-kbp deletion in CLN3 that causes Batten disease | Q35790328 | ||
Genetic modulation of apoptotic pathways fails to alter disease course in tripeptidyl-peptidase 1 deficient mice | Q37188640 | ||
Towards understanding the neuronal ceroid lipofuscinoses. | Q37386152 | ||
A clinical rating scale for Batten disease: reliable and relevant for clinical trials | Q47613398 | ||
Neuronal ceroid lipofuscinoses | Q56566989 | ||
P433 | issue | 5 | |
P921 | main subject | juvenile neuronal ceroid lipofuscinosis | Q1753778 |
P304 | page(s) | 1075-1081 | |
P577 | publication date | 2011-05-10 | |
P1433 | published in | Journal of Inherited Metabolic Disease | Q6295359 |
P1476 | title | Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data | |
P478 | volume | 34 |
Q47826326 | Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy. |
Q36986268 | Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis |
Q67231335 | Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis |
Q37659610 | Clinical trials in rare disease: challenges and opportunities |
Q58779774 | Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses |
Q37021406 | Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates |
Q35840603 | Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs). |
Q36556394 | Reliability and validity of the Wolfram Unified Rating Scale (WURS). |
Search more.